NovaDel Announces Update on Experimental Lingual Spray Drug Will Be Presented at Anesthesia Meeting FLEMINGTON, N.J., April 14 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc. (BULLETIN BOARD: NVDL) said an update on a lingual spray formulation of propofol, the world's leading intravenous general anesthetic, will be presented by its licensee and development partner, Manhattan Pharmaceuticals, Inc. (BULLETIN BOARD: MHTT) , at the 19th Annual Meeting of the Society for Ambulatory Anesthesia, Seattle, April 29-May 2. Manhattan scientists will describe recent progress in developing the proprietary sedative in a presentation titled, "Propofol Lingual Spray: Formulation Optimization and Stability". In June 2003, Manhattan and NovaDel announced a joint program to develop a safe, convenient, noninvasive lingual spray version of the widely used sedative. The two companies believe the delivery of propofol via lingual spray may provide many advantages over currently formulated sedatives. The product would be indicated for patients undergoing in office or out patient diagnostic or therapeutic procedures for which clinicians seek to tightly control the onset, duration, and depth of sedation, with a level of reliability and accuracy presently unachievable with existing sedatives. The intended benefits are expected to be better procedural outcomes and higher degrees of patient comfort and satisfaction. Manhattan owns the worldwide, exclusive rights to use NovaDel's proprietary lingual spray technology to deliver propofol for preprocedural sedation. About NovaDel Pharma Inc. NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the development of novel drug delivery systems for prescription and over-the-counter drugs. The Company's proprietary lingual spray technology delivery system offers the patient (i) fast onset of action; (ii) improved drug safety by reducing the required drug dosage and reducing side effects; (iii) improved patient convenience and compliance; and (iv) enhanced dosage reliability. The Company plans to develop such products independently and through collaborative arrangements with major pharmaceutical and biotech companies. Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein including, but not limited to, the ability to develop products (independently and through collaborative arrangements), and the ability to commercialize and obtain approval for products under development. Further, the Company operates in industries where securities may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's most recent Annual Report and Registration Statements, filed with the Securities and Exchange Commission. In assessing forward-looking statements contained herein, if any, the reader is urged to carefully read all cautionary statements contained in such filings. Contact: Barry C. Cohen VP Business & New Product Development 908 782-3431 x 2160 NovaDel Pharma Inc. Thomas Redington 203 222-7399 212 926-1733 DATASOURCE: NovaDel Pharma, Inc. CONTACT: Barry C. Cohen, VP Business & New Product Development of NovaDel Pharma Inc., +1-908-782-3431, ext. 2160; or Thomas Redington, +1-203-222-7399, +1-212-926-1733, , for NovaDel Pharma Inc.

Copyright